

Supplemental Figures




Figure S1: Endogenous cortical GPCR-β8 signaling dynamics during development

(A-E) DAPI images of cortex from embryonic day 13 (E13) to E17.

(A'-E') Phospho-p38 (p-p-38) staining of cortex from E13-E17.

(F) Quantification of immunofluorescence of phospho-p38 staining. (E13: n = 5; E14: n = 10, E15: n = 12, E16: n = 3, E17: n = 7; $p = 0.0032, 0.0001$)

(G) Quantitative PCR (q-PCR) of integrin β8 gene expression from E13.5 E17.5 in the cortex.

(E13: n = 8; E14: n = 7, E15: n = 5, E16: n = 7, E17: n = 4)




Figure S2: DREADD activation at E15 does not induce $\beta 8$ pathway in the cortex

(A) Quantification of p-p38 cortical staining in WT and Gi+Gq brains 1.5 hours after CNO injection at E15 (ctl: n=9, Gi+Gq: n=7)

(B) q-PCR of integrin $\beta 8$ gene expression 8 hours after CNO injection at E15 in wild type and Gi+Gq brains (ctl: n=5, Gi+Gq: n=4).




Figure S3: Cortical vessel morphology is not affected by E15 DREADD activation

(A-A') DAPI staining of cortex of wild type and Gi+Gq P0 brains after CNO injection at E15.

(B-B') IB4 staining of cortical vessels in wild type and Gi+Gq P0 brains after CNO injection at E15.

(C-C') DAPI and IB4 merge

(D-E) Quantification of cortical vessel density (WT+CNO: *n* = 6, Gi+Gq+CNO: *n* = 7; *p* = 0.65)

(D) and branching frequency (WT+CNO: *n* = 6, Gi+Gq+CNO: *n* = 7; *p* = 0.32) (E) in wild type and Gi+Gq after 1 mg/kg CNO injection at E15.

(F-G) Quantification of GM vessel density in WT + CNO (*n* = 21), Gi+Gq without CNO (*n* = 14), and Gi+Gq + CNO (*n* = 13; *p* = 0.002) (F) and branching frequency WT + CNO (*n* = 21), Gi+Gq without CNO (*n* = 14), and Gi+Gq + CNO (*n* = 13; *p* = 0.0004) (G) in wild type and Gi+Gq brains after a single injection of 1 mg/kg of CNO at E15.




Figure S4: CNO injection at various developmental stages shows only E15 activation has effects on GM vessel morphology

(A) Quantification of phospho-Smad3-positive ECs along vessels in the GM 16 hours after CNO injection at E14 in wild type and Gi+Gq brains.

(B) Quantification of phospho-Smad3-positive ECs along vessels in the GM 16 hours after CNO injection at E16 in wild type and Gi+Gq brains.

(C) Quantification of vessel density in GM at P0 after single injection of CNO at one developmental stage in wild type and Gi+Gq expressing brains (E11-E17).

(D) Quantification of vessel branching in GM at P0 after single injection of CNO at one developmental stage in wild type and Gi+Gq expressing brains (E11-E17).




Figure S5. 0.75x CNO injection at E15 does not significantly affect Glut-1 expression or pericyte density.

(A-B'') Glut-1 and IB4 staining of GM vessels in wild type (A-A'') and Gi+Gq (B-B'') E17 brains after 0.75x CNO injection at E15.

(C) Quantification of Glut-1 intensity along vessels in the GM at E17 after 0.75x CNO injection at E15 in wild type and Gi+Gq animals ($p = 0.94$; $n = 8$).

(D) Quantification of NG2-positive pericytes along vessels in the GM at E17 after 0.75x CNO injection at E15 in wild type and Gi+Gq animals ($p = 0.10$; $n = 7$).

Table S1. Resources and reagents

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|--------------------------------------|---|---|
| Antibodies | | |
| Rabbit anti-laminin | Sigma-Aldrich | Cat # L9393; RRID: AB_477163 |
| Biotinylated Isolectin B4 | Vector Laboratories | Cat # B-1205; RRID: AB_2314661 |
| Rat anti-Ter119 | BD Pharmingen | Cat # 553986; RRID: AB_2650605 |
| Rabbit anti-Phospho-p38 | Cell Signaling | Cat # 4511; RRID: AB_2139682 |
| Rabbit anti-Collagen IV | Abcam Bio-Rad | Cat# ab15633, RRID: AB_302010 Cat # 2150-1470 RRID: AB_2082660 |
| Rabbit anti-GFAP | Dako | Cat # Z 0334; RRID: AB_10013382 |
| Rabbit anti-Glut1 | Thermo Scientific | Cat# RB-9052-P0; RRID: AB_177894 |
| FITC conjugated secondary antibodies | Jackson ImmunoResearch Laboratories | Cat # 111-095-003; RRID: AB_2337972 |
| Cy3 conjugated secondary antibodies | Jackson ImmunoResearch Laboratories | Cat # 711-165-152; RRID: AB_2307443 Cat # 111-165-144; |

| | | |
|--|---|--|
| | | RRID: AB_2338006 |
| FITC conjugated streptavidin | Jackson ImmunoResearch Laboratories | Cat # 016-010-084; RRID: AB_2337236 |
| Peroxidase conjugated secondary antibodies | Santa Cruz Biotech | Cat # SC-2004; RRID: AB_631746 Cat # SC-2005; RRID: AB_631736 |
| Chemicals, Peptides, and Recombinant Proteins | | |
| S1P | Cayman Chemical | Cat # 62570 |
| JTE-013 | Cayman Chemical | Cat # 10009458 |
| TY 52156 | Tocris | Cat # 5328 |
| CNO | APExBIO Tocris | Cat #: A3317 Cat #: 4936 |
| | | |
| Critical Commercial Assays | | |
| Tyramide signal amplification (TSA) plus Cy3 kit | PerkinElmer, Waltham, MA | Cat # NEL744E001KT |
| GoTaq qPCR master mix | Promega | Cat # A6002 #TM318 |
| Experimental Models: Organisms/Strains | | |

| | | |
|--|-------------|---------------------------------------|
| Ric8a conditional allele | Our own lab | Ma et al., 2012 (40) |
| S1pr1 conditional allele | JAX | JAX: 019141 Allende et al., 2003 |
| Nestin-cre | JAX | JAX: 003771 Tronche et al., 1999 |
| ROSA:LNL:tTA | JAX | JAX: 011008 Wang et al., 2008 |
| TRE-hM3Dq | JAX | JAX: 014093 Alexander et al., 2009 |
| TRE-hM4Di | JAX | JAX: 024114 |
| | | |
| Oligonucleotides | | |
| GAPDH: F-tgcccccatgtttgtgatg, R- tgtggatcatgagcccttc | Our own lab | |
| integrin β 8: F- ccagtactgtgagaaggatgac, R- agttgacacagtgctgtgctga | Our own lab | |
| integrin β 3: F- tggagacacctgtgtgagaag, R- ttcacctgctgatgcatc | Our own lab | |
| integrin β 5: F- tctgcttcgagagtgagtt, R- ttctccacagtgacactctcc | Our own lab | |
| integrin α : F- gagtacttctcgggtggtcct, R- ggggggctccaataaacaca | Our own lab | |

| | | |
|--|----------------------------|--|
| Nestin: F- cgctcagatcctggaaggtg, R- ttctcagcctccagcagagt | Our own lab, this paper | |
| | | |
| Software and Algorithms | | |
| ImageJ | | |